122 related articles for article (PubMed ID: 21500491)
1. [Efficacy of prostatic adenoma treatment with alfusozine depending on sexuality].
Kogan MI; Kireev AIu
Urologiia; 2011; (1):28-31. PubMed ID: 21500491
[TBL] [Abstract][Full Text] [Related]
2. Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia.
Yokoyama T; Hara R; Fukumoto K; Fujii T; Jo Y; Miyaji Y; Nagai A; Sone A
Int J Urol; 2011 Mar; 18(3):225-30. PubMed ID: 21272091
[TBL] [Abstract][Full Text] [Related]
3. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction.
Broderick GA; Brock GB; Roehrborn CG; Watts SD; Elion-Mboussa A; Viktrup L
Urology; 2010 Jun; 75(6):1452-8. PubMed ID: 20163842
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of sexual function in men with symptomatic benign prostatic hyperplasia].
Shao Q; Song J; Guo YW; Lu WC; Du LD
Zhonghua Nan Ke Xue; 2005 Jul; 11(7):505-7. PubMed ID: 16078666
[TBL] [Abstract][Full Text] [Related]
5. Sexuality and management of benign prostatic hyperplasia with alfuzosin: SAMBA Thailand.
Leungwattanakij S; Watanachote D; Noppakulsatit P; Petchpaibuol T; Choeypunt N; Tongbai T; Wanamkang T; Lojanapiwat B; Permpongkosol S; Tantiwong A; Pripatnanont C; Akarasakul D; Kongwiwatanakul S; Chotikawanich E
J Sex Med; 2010 Sep; 7(9):3115-26. PubMed ID: 20233288
[TBL] [Abstract][Full Text] [Related]
6. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
Kaplan SA; Gonzalez RR; Te AE
Eur Urol; 2007 Jun; 51(6):1717-23. PubMed ID: 17258855
[TBL] [Abstract][Full Text] [Related]
7. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
[TBL] [Abstract][Full Text] [Related]
8. A prospective, randomized, controlled, multicenter study of naftopidil for treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: 75 mg once daily in the evening compared to 25 mg thrice daily.
Tsuritani S; Nozaki T; Okumura A; Kimura H; Kazama T
Urol Int; 2010; 85(1):80-7. PubMed ID: 20516676
[TBL] [Abstract][Full Text] [Related]
9. An open, non-comparative, multicentre study on the impact of alfuzosin on sexual function using the Male Sexual Health Questionnaire in patients with benign prostate hyperplasia.
Kim MK; Cheon J; Lee KS; Chung MK; Lee JY; Lee SW; Kim SW; Chung BH; Park K; Park JK
Int J Clin Pract; 2010 Feb; 64(3):345-50. PubMed ID: 19891715
[TBL] [Abstract][Full Text] [Related]
10. Sexuality and the management of BPH with alfuzosin (SAMBA) trial.
Chung BH; Lee JY; Kim CI; Kim CS; Oh CY; Lee SW; Lee JS; Yoo SJ
Int J Impot Res; 2009; 21(1):68-73. PubMed ID: 19078970
[TBL] [Abstract][Full Text] [Related]
11. Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia.
Rosen R; Seftel A; Roehrborn CG
Int J Impot Res; 2007; 19(5):480-5. PubMed ID: 17717526
[TBL] [Abstract][Full Text] [Related]
12. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.
Li MK; Garcia L; Patron N; Moh LC; Sundram M; Leungwattanakij S; Pripatnanont C; Cheng C; Chi-Wai M; Loi-Cheong N
BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
de Reijke TM; Klarskov P
BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
[TBL] [Abstract][Full Text] [Related]
14. [Lower urinary tract symptoms are poorly correlated with erectile dysfunction].
Marionneau N; Perrin P; Taieb C
Prog Urol; 2006 Nov; 16(5):572-7. PubMed ID: 17175954
[TBL] [Abstract][Full Text] [Related]
15. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.
Lukacs B; Leplège A; Thibault P; Jardin A
Urology; 1996 Nov; 48(5):731-40. PubMed ID: 8911517
[TBL] [Abstract][Full Text] [Related]
16. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
Carson CC
BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
[TBL] [Abstract][Full Text] [Related]
17. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E
Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250
[TBL] [Abstract][Full Text] [Related]
18. [The evaluation of efficacy and safety of treatment with dalfaz SR in patients with prostatic adenoma].
Rasner PI; Pushkar' DIu
Urologiia; 2013; (3):34-6, 38. PubMed ID: 23987046
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
Nordling J
BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
[TBL] [Abstract][Full Text] [Related]
20. [Results of treatment of patients with prostatic adenoma using silodosin based on an assessment of the phenotype of male sexuality].
Kogan MI; Kireev AIu
Urologiia; 2013; (6):58-60. PubMed ID: 24649766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
